FBT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FB

Volume

49.24K

Loading chart

FB

FBTFirst Trust NYSE Arca Biotechnology Index Fund

FBT

Pay with—

Available Balance0.00

FB

AUM

N/A

Volume

49.24K

Yield

1.78%

Chart Earnings News About Insider Filings

Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateBiotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.Zacks Investment Research · Sep 21, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.Zacks Investment Research · Sep 1, 2026

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.The Motley Fool · Jul 23, 2026

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.The Motley Fool · Jul 21, 2026

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.The Motley Fool · Jul 12, 2026

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT's stronger 10-year performance, PJP is recommended as the better buy due to its superior 5-year returns, lower volatility, dividend yield, and more stable risk profile.The Motley Fool · Jul 8, 2026

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated biotech exposure with 30 holdings. The analysis concludes XPH is the more appealing long-term choice due to its lower fees and superior performance.The Motley Fool · Jun 4, 2026

FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock SoarsThe FDA has reversed its previous refusal-to-file decision and accepted Moderna's biologics license application for mRNA-1010, an mRNA-based flu vaccine for adults 50 and older, with an August 5 PDUFA goal date. The stock surged 5.77% on the news. Moderna also beat Q4 earnings expectations with a smaller loss and higher-than-expected revenue of $678 million.Benzinga · Feb 18, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.Zacks Investment Research · Aug 6, 2024

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?Smart Beta ETF report for XBIZacks Investment Research · Jun 25, 2024

to start trading

FB

FBTFirst Trust NYSE Arca Biotechnology Index Fund

FBT

Pay with—

Available Balance0.00

Your PositionYou don't own any FBT yet.

Related Tickers

Earnings